drugset / Trial / NCT02656173
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
Timeline
- Start
- 2016-01-25
- Primary completion
- 2017-07-21
- Completion
- 2017-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 50 mg | Oral |
| Background | Tamsulosin | Other / unclassified | 0.2 mg | Oral |